Meyrin, Switzerland
Terapet is a Switzerland-based startup that focuses on revolutionizing cancer treatment with its cutting-edge technology in proton therapy. Founded in 2019 by two CERN physicists and a leading radio-oncologist from Geneva, the company aims to address the current limitations in proton therapy, which is regarded as the most accurate form of radiotherapy for cancer treatment. Despite its potential, the lack of a real-time dose verification system has hindered its widespread adoption.
The company's €1.68M grant investment from Eurostars on 06 March 2024 underscores the belief in its innovative approach. Terapet's state-of-the-art dose verification system for proton therapy ensures precise dosage and treatment location, thereby minimizing harm to healthy tissue. By providing real-time verification, the technology addresses a critical need in the field of cancer treatment, potentially surpassing traditional methods.
Operating in the Health Care industry, Terapet proposes a solution to the challenges associated with proton therapy, demonstrating its potential to significantly enhance the effectiveness of cancer treatment. With its strong founding team and backing from prominent investors, the company positions itself as a promising player in advancing cancer treatment technologies.
